Aimmune Therapeutics Stock Forecast, Price & News

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aimmune Therapeutics in the last twelve months. There are currently 5 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Aimmune Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AIMT, but not buy additional shares or sell existing shares.
View analyst ratings for Aimmune Therapeutics or view top-rated stocks.

Wall Street analysts have given Aimmune Therapeutics a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Aimmune Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Aimmune Therapeutics, Inc. (NASDAQ:AIMT) posted its quarterly earnings results on Thursday, July, 30th. The biotechnology company reported ($1.06) earnings per share for the quarter, meeting the Thomson Reuters' consensus estimate of ($1.06).
View Aimmune Therapeutics' earnings history.

5 brokerages have issued 12-month price targets for Aimmune Therapeutics' shares. Their forecasts range from $18.00 to $35.00. On average, they anticipate Aimmune Therapeutics' share price to reach $31.30 in the next year. This suggests that the stock has a possible downside of 9.2%.
View analysts' price targets for Aimmune Therapeutics or view top-rated stocks among Wall Street analysts.

Some companies that are related to Aimmune Therapeutics include BridgeBio Pharma (BBIO), United Therapeutics (UTHR), Biohaven Pharmaceutical (BHVN), Mirati Therapeutics (MRTX), HUTCHMED (HCM), Arrowhead Pharmaceuticals (ARWR), Evotec (EVTCY), Legend Biotech (LEGN), Perrigo (PRGO), Ascendis Pharma A/S (ASND), I-Mab (IMAB), Cassava Sciences (SAVA), Sarepta Therapeutics (SRPT), Apellis Pharmaceuticals (APLS) and Ultragenyx Pharmaceutical (RARE).
View all of AIMT's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aimmune Therapeutics investors own include Hawkins (HWKN), NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Square (SQ), AbbVie (ABBV), Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Advanced Micro Devices (AMD) and Roku (ROKU).

(AIMT) raised $124 million in an IPO on Thursday, August 6th 2015. The company issued 8,300,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Credit Suisse and Piper Jaffray served as the underwriters for the IPO.

Aimmune Therapeutics trades on the NASDAQ under the ticker symbol "AIMT."

One share of AIMT stock can currently be purchased for approximately $34.49.

Aimmune Therapeutics has a market capitalization of $2.26 billion. The biotechnology company earns $-248,500,000.00 in net income (profit) each year or ($3.97) on an earnings per share basis.

Aimmune Therapeutics employs 228 workers across the globe.

The official website for Aimmune Therapeutics is www.aimmune.com.

Aimmune Therapeutics is headquartered at 8000 MARINA BOULEVARD SUITE 300, BRISBANE CA, 94005.

Aimmune Therapeutics' mailing address is 8000 MARINA BOULEVARD SUITE 300, BRISBANE CA, 94005. The biotechnology company can be reached via phone at 650-614-5220 or via email at [email protected]